Nowadays, with the broad use of immune checkpoint inhibitors for cancer treatment, the PD-L1-status (programmed death-ligand 1-status) opens up a further therapeutic option in cases of NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.